S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

ESSA Pharma Stock Forecast, Price & News

+0.25 (+0.93 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $27.06
50-Day Range
MA: $21.78
52-Week Range
Now: $27.06
Volume401,103 shs
Average Volume449,690 shs
Market Capitalization$867.65 million
P/E RatioN/A
Dividend YieldN/A
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma logo


EPIX: Encouraging Initial Clinical Data for EPI-7386…
February 12, 2021 |  finance.yahoo.com
EPIX: Clinical Data for EPI-7386 in 2021…
December 17, 2020 |  finance.yahoo.com
Is EPIX A Good Stock To Buy Now?
December 15, 2020 |  finance.yahoo.com
Boyd Group Services Inc. Reports Third Quarter 2020 Results
November 11, 2020 |  finance.yahoo.com
ESSA Pharma to Participate in Upcoming Investor Conferences
November 10, 2020 |  finance.yahoo.com
ESSA Pharma to delist from from TSX-V
October 27, 2020 |  seekingalpha.com
ESSA Pharma completes $49M aggregate gross proceeds
July 31, 2020 |  seekingalpha.com
ESSA Pharma prices equity offering at $6/share
July 29, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EPIX
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$2.47 per share


Net Income$-23,440,000.00


Market Cap$867.65 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.42 out of 5 stars

Medical Sector

581st out of 1,969 stocks

Pharmaceutical Preparations Industry

270th out of 771 stocks

Analyst Opinion: 1.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
+0.25 (+0.93 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions

Is ESSA Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ESSA Pharma stock.
View analyst ratings for ESSA Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than ESSA Pharma?

Wall Street analysts have given ESSA Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ESSA Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a increase in short interest in February. As of February 12th, there was short interest totaling 62,700 shares, an increase of 37.5% from the January 28th total of 45,600 shares. Based on an average daily volume of 324,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.4% of the company's stock are sold short.
View ESSA Pharma's Short Interest

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for ESSA Pharma

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) posted its earnings results on Thursday, February, 11th. The company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.03.
View ESSA Pharma's earnings history

How has ESSA Pharma's stock been impacted by COVID-19 (Coronavirus)?

ESSA Pharma's stock was trading at $4.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EPIX stock has increased by 564.9% and is now trading at $27.06.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EPIX?

5 Wall Street analysts have issued 1-year price targets for ESSA Pharma's shares. Their forecasts range from $9.00 to $50.00. On average, they anticipate ESSA Pharma's share price to reach $28.80 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price.
View analysts' price targets for ESSA Pharma
or view top-rated stocks among Wall Street analysts.

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the following people:
  • Dr. David Ross Parkinson, Pres, CEO & Director (Age 71, Pay $788.6k)
  • Mr. Peter A. Virsik M.B.A., M.S., Exec. VP & COO (Age 50, Pay $615.59k)
  • Dr. Alessandra Cesano, Chief Medical Officer
  • Mr. David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer (Age 64)
  • Chandtip Chandhasin, Exec.
  • Erica Osbourne, Exec.
  • Erin Rudsinski, Exec.
  • Leah Dimascio, Exec.
  • Loleta Harris, Exec.
  • Neil Thapar, Exec.

Who are some of ESSA Pharma's key competitors?

What other stocks do shareholders of ESSA Pharma own?

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Avidity Partners Management LP (7.98%), Janus Henderson Group PLC (1.59%), Morgan Stanley (1.46%), Orbimed Advisors LLC (1.44%), Silverarc Capital Management LLC (1.01%) and Opaleye Management Inc. (0.89%).
View institutional ownership trends for ESSA Pharma

Which major investors are selling ESSA Pharma stock?

EPIX stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for ESSA Pharma
or view top insider-selling stocks.

Which major investors are buying ESSA Pharma stock?

EPIX stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Silverarc Capital Management LLC, Rhenman & Partners Asset Management AB, Morgan Stanley, Pura Vida Investments LLC, Janus Henderson Group PLC, Opaleye Management Inc., and Prelude Capital Management LLC.
View insider buying and selling activity for ESSA Pharma
or or view top insider-buying stocks.

How do I buy shares of ESSA Pharma?

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $27.06.

How much money does ESSA Pharma make?

ESSA Pharma has a market capitalization of $867.65 million. The company earns $-23,440,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does ESSA Pharma have?

ESSA Pharma employs 25 workers across the globe.

What is ESSA Pharma's official website?

The official website for ESSA Pharma is www.essapharma.com.

Where are ESSA Pharma's headquarters?

ESSA Pharma is headquartered at 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.